What one share of Black Diamond Therapeutics holds
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry.
Black Diamond Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.74 |
| Cash and investments | $0.33 |
| Book value | $1.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.00 | −$4.42 | $0.04 | −$4.23 | — | −$7.15 |
| 2019 | $0.00 | −$16.99 | $0.01 | −$11.90 | — | −$21.08 |
| 2020 | $0.00 | −$2.04 | $0.00 | −$1.59 | — | $8.53 |
| 2021 | — | −$3.47 | $0.07 | −$2.84 | — | $5.41 |
| 2022 | — | −$2.51 | $0.01 | −$2.35 | — | $3.18 |
| 2023 | — | −$1.88 | $0.00 | −$1.52 | — | $2.26 |
| 2024 | $0.00 | −$1.27 | $0.00 | −$1.13 | — | $1.47 |
| 2025 | $1.22 | $0.39 | — | — | — | $1.96 |
Common questions about Black Diamond Therapeutics
How much does one share of Black Diamond Therapeutics earn?
Over the last 12 months, Black Diamond Therapeutics lost $0.74 for each share.
Does Black Diamond Therapeutics pay a dividend?
Black Diamond Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Black Diamond Therapeutics’s book value per share?
Black Diamond Therapeutics’s book value is $1.67 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Black Diamond Therapeutics have?
Each share of Black Diamond Therapeutics has $0.33 of cash and investments, as of June 30, 2026.
Has Black Diamond Therapeutics bought back shares?
Black Diamond Therapeutics’s share count rose about 2752% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.